BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

09 8 2024 09:45:50 提供 NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

07 8 2024 09:45:08 提供 NetDania Notify

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

05 8 2024 07:00:24 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 8 2024 07:00:47 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

29 7 2024 09:56:40 提供 NetDania Notify

BioCryst to Report Second Quarter 2024 Financial Results on August 5

22 7 2024 07:00:09 提供 Nasdaq GlobeNewswire

ORLADEYO® (berotralstat) Approved in Peru

09 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 7 2024 07:00:06 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 6 2024 07:00:59 提供 Nasdaq GlobeNewswire

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

02 6 2024 04:00:13 提供 Nasdaq GlobeNewswire

BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology

14 5 2024 07:00:53 提供 Nasdaq GlobeNewswire

ORLADEYO® (berotralstat) Approved in Mexico

13 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)

09 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

07 5 2024 07:00:22 提供 Nasdaq GlobeNewswire

BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

06 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 5 2024 07:00:07 提供 Nasdaq GlobeNewswire

BioCryst to Report First Quarter 2024 Financial Results on May 6

22 4 2024 07:00:50 提供 Nasdaq GlobeNewswire

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

17 4 2024 04:30:39 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 4 2024 07:00:23 提供 Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

25 3 2024 16:01:00 提供 Nasdaq GlobeNewswire